Dice CEO: Energy, T...
Health Care: Drugs
DUSA Pharmaceuticals Inc. (DUSA: NASDAQ)
$4.91 -0.25 | -4.84%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 16.90 | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 0.86 | 0.62 | 0.98 |
| Price to Sales (TTM) | 2.57 | 4.29 | 1.42 |
| Price to Book (MRQ) | 4.35 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 4.35 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | 15.10 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | 17.20 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 21.10 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 21.00 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 10.80 | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -42.78 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.80 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 6.60 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.37 | 0.96 |
| Interest Coverage (TTM) | n.a. | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 85.90 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 80.20 | 75.30 | 47.70 |
| EBITD Margin (TTM) | 17.40 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | -43.17 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 14.80 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -8.20 | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.15 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -7.90 | 8.60 | 7.00 |
| Return on Assets (TTM) | 19.50 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | -8.80 | 4.60 | 2.50 |
| Return on Investment (TTM) | 26.90 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -13.00 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 496,195.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | 79,035.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 15.70 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 2.30 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 1.40 | 0.60 | 0.40 |
Portfolios with DUSA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorTop-Rated Biotechnology Stocks
- UserThatBobGuy Portfolio 1
- ContributorBarron's Insider Purchases ...
- ContributorTop 10 Insider Purchases: J...
- Userjoshuparks Portfolio 1
- Uservladys buttom fishing
- Userbill 3
- UserHeld's
Latest DUSA Headlines from TheStreet
- 8 Stocks Under $10 Ripping Higher 05.03.12 | 01:05 pm
- DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA) 11.14.11 | 06:11 am
- DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA) 07.28.11 | 07:07 am
- DUSA Stock Hits New 52-Week High (DUSA) 05.25.11 | 10:05 am
- DUSA Stock Soars (DUSA) 05.05.11 | 10:05 am
- DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA) 03.04.11 | 05:03 pm
- DUSA Stock Soars Higher (DUSA) 03.03.11 | 10:03 am
- Cautious Bull
03.08.10 | 11:03 am - The Pisani Paradox 09.28.09 | 11:09 am
- Wednesday's Health Winners & Losers 10.03.07 | 03:10 pm
Press Releases for DUSA
- DUSA Pharmaceuticals, Inc.® To Host First Quarter 2011 Corporate Highlights And Financial Results Webcast And Conference Call - Business Wire 04.28.11 | 08:04 am
- A Patient Receiving Levulan Photodynamic Therapy. (Photo: Business Wire) - Business Wire 03.03.11 | 06:03 am
- DUSA Pharmaceuticals, Inc.® To Host Fourth Quarter And Full Year 2010 Corporate Highlights And Financial Results Conference Call - Business Wire 02.25.11 | 06:02 am
- DUSA Pharmaceuticals To Present At The 4th Annual Maxim Group Growth Conference - PR Newswire 11.11.10 | 08:11 am
- DUSA Pharmaceuticals Named To Deloitte's 2010 Technology Fast 500 List Of Fastest Growing Companies In North America - PR Newswire 10.26.10 | 03:10 pm
- DUSA Pharmaceuticals To Present At The Rodman & Renshaw 12th Annual Healthcare Conference - PR Newswire 09.07.10 | 08:09 am
- DUSA Pharmaceuticals Receives Response From FDA On Orphan Drug Designation Status - PR Newswire 08.06.10 | 12:08 pm
- DUSA Pharmaceuticals Reports U.S. Patent Office Upholds Key Photodynamic Therapy Patent - PR Newswire 06.24.10 | 06:06 am
- DUSA Pharmaceuticals Announces Slate Of Nominees For Election To The Board Of Directors - PR Newswire 05.13.10 | 12:05 pm
- DUSA Pharmaceuticals Reports Notice Of Allowance For Key PDT Device Patent - PR Newswire 05.07.10 | 06:05 am
Partner Headlines for DUSA
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 03.30.12 | 09:03 am
- DUSA Pharmaceuticals Is A Small Gem - Seeking Alpha 12.23.11 | 02:12 pm
- 20 Smart Money Stock Picks Trading Under $5 - Seeking Alpha 11.03.11 | 07:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.01.11 | 09:07 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 03.07.11 | 09:03 am
- Morning Market Movers (GTEC, ASGR, LSBK, DUSA) - Benzinga 03.03.11 | 09:03 am
- UPDATE 1-DUSA to end skin drug deal with Stiefel Laboratories - Reuters 10.06.10 | 08:10 am
- UPDATE 1-DUSA to stop cancer trial as FDA denies orphan status - Reuters 08.06.10 | 02:08 pm
